Ibrahim Şahin

Nov 20, 2024 | mdpi.com | Onur Yigit |Ibrahim H. Sahin |İbrahim YILDIZ-Uğur ŞAHİN |Ibrahim Şahin |Selin Genc |Bahri Evren

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

May 15, 2024 | cancernetwork.com | Seth I. Felder |Jessica Frakes |Manju George |Allison B. Rosen |Ibrahim Halil Sahin |Ibrahim Şahin

May 15, 2024OncologyONCOLOGY Vol 38, Issue 5Pages: 187-190Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.

Sep 7, 2023 | mdpi.com | Akshit Chitkara |Muhammad Arsalan Bakhtiar |Ibrahim Halil Sahin |Ibrahim Şahin |Dennis J. Hsu

3. Results 3.1. Study CharacteristicsTwo of the six trials selected evaluated trastuzumab deruxtecan, and one evaluated trastuzumab plus lapatinib. One trial evaluated pertuzumab plus trastuzumab emtansine, while one evaluated trastuzumab plus tucatinib, and one evaluated trastuzumab plus pyrotinib (Table 2). Regarding prior lines of treatment, the median number of prior lines was two and three in two trials and four and five in one trial each.

Nov 14, 2022 | cancernetwork.com | Ibrahim Şahin

Oct 14, 2022 | cancernetwork.com | Ibrahim Şahin